2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Abstract Full Text (PDF) All Versions of this Article: ASN.2005080872v1 17/6/1703    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sochett, E. B. Articles by Miller, J. A. Search for Related Content PubMed PubMed Citation Articles by Sochett, E. B. Articles by Miller, J. A.

Impact of Renin Angiotensin System Modulation on the Hyperfiltration State in Type 1 Diabetes

Etienne B. Sochett^*, David Z.I. Cherney, Jacqueline R. Curtis^*, Maria G. Dekker^*, James W. Scholey and Judith A. Miller

^* Division of Endocrinology, Hospital for Sick Children; and Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada

Address correspondence to: Dr. Judith A. Miller, Toronto General Hospital, 585 University Avenue, 8N-846, Toronto, Ontario, M5G 2N2, Canada. Phone: 416-340-4966; Fax: 416-340-4951; E-mail: judith.miller{at}utoronto.ca

Received for publication August 22, 2005. Accepted for publication March 23, 2006.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
The initial stages of diabetic nephropathy are characterized by glomerular hyperfiltration and hypertension, processes that have been linked to initiation and progression of renal disease. Renin angiotensin system (RAS) blockade is commonly used to modify the hyperfiltration state and delay progression of renal disease. Despite this therapy, many patients progress to ESRD, suggesting heterogeneity in the response to RAS modulation. The role of the RAS in the hyperfiltration state in adolescents with uncomplicated type 1 diabetes was examined, segregated on the basis of the presence of hyperfiltration. Baseline renal hemodynamic function was characterized in 22 patients. Eleven patients exhibited glomerular hyperfiltration (GFR 135 ml/min), and in the remaining 11 patients, the GFR was <130 ml/min. Renal hemodynamic function was assessed in response to a graded angiotensin II (AngII) infusion during euglycemic conditions and again after 21 d of angiotensin-converting enzyme (ACE) inhibition with enalapril. AngII infusion under euglycemic conditions resulted in a significant decline in GFR and renal plasma flow in the hyperfiltration group but not in the normofiltration group. After ACE inhibition, GFR fell but did not normalize in the hyperfiltration group; the normofiltration group showed no change. These data show significant differences in renal hemodynamic function between hyperfiltering and normofiltering adolescents with type 1 diabetes at baseline, after AngII infusion and ACE inhibition. The response to ACE inhibition and AngII in hyperfiltering patients suggests that vasodilation may complement RAS activation in causing the hyperfiltration state. The interaction between glomerular vasoconstrictors and vasodilators requires examination in future studies.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
Diabetic nephropathy is the single most important cause of renal failure in North America, accounting for >40% of prevalent cases (1). The initial stages of renal disease are characterized by renal hemodynamic alterations that result in increased intraglomerular pressure and glomerular hyperfiltration (2–4). This in turn has been associated with cytokine- and growth factor–mediated cell and connective tissue proliferation and fibrosis, mostly on the basis of TGF- upregulation (5). Several studies (1,6) have linked hyperfiltration to the initiation and progression of diabetic nephropathy. Although some earlier experiments suggested renin angiotensin system (RAS) blunting as the cause of the hyperfiltration state, partly on the basis of decreases in circulating RAS components (7), more recent studies in humans (8) and animals (7) have confirmed that the intrarenal RAS is activated, especially in response to hyperglycemia (6). RAS blockade is currently a well-established therapy in type 1 diabetes (9–13). Although early RAS blockade decreases the relative risk for reaching clinical end points such as time to doubling of serum creatinine, dialysis, or death (9–11); delays the progression from microalbuminuria to macroalbuminuria (9–12); and ameliorates pathologic changes such as glomerular basement membrane thickening (13), it does not completely arrest the progression of diabetic nephropathy in all patients (9–13).

In this study, we describe the renal hemodynamic responses to graded angiotensin II (AngII) infusion and to angiotensin-converting enzyme (ACE) inhibition in a group of normotensive, normoalbuminuric adolescents who had type 1 diabetes and were segregated into groups on the basis of the presence or absence of hyperfiltration. We hypothesized that the hemodynamic response to RAS modulation (incremental AngII infusion and ACE inhibition) would not be uniform in these two groups of patients. Our aim was to examine the role of RAS function in the hyperfiltration state and to determine the utility of RAS blockade as a modifier of hyperfiltration.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
Patients
Participants who fulfilled the following inclusion criteria were asked to participate: Duration of type 1 diabetes >5 yr, Tanner stages 2 to 5 puberty, normoalbuminuria (albumin excretion rate [AER] <20 µg/min on two of three overnight urine collections obtained during the month before study), normal clinic BP, no microvascular disease, and absence of chronic illness other than treated hypothyroidism or mild asthma. The Research Ethics Board at the Hospital for Sick Children (Toronto, Ontario, Canada) approved the protocol. All patients and/or their parents gave informed consent. Twenty-two adolescents with type 1 diabetes were eligible to participate.

Protocol and Evaluations
Patients adhered to a sodium-replete (150 to 200 mmol/d) and moderate-protein (1 to 1.5 g/kg per d) diet during the 7-d period before each experiment. Diets were evaluated twice during the month leading up to the study and also on days 5 and 6. For ascertainment of compliance, patients underwent an overnight urine collection to determine the urinary sodium and urea excretion on days 5 and 6. Protein intake was calculated from the urea excretion using standard methods (14). Patients were studied when the excretion of sodium and urea was 2 to 3 and 3 to 6 mmol/kg, respectively, in 24 h. All patients met these study criteria. Patients also had ambulatory BP monitoring performed on three occasions leading up to the experiment. We measured average 24-h systolic BP (SBP) and diastolic BP (DBP) as well as night-day (N/D) ratio. Although other valid methods exist for defining N/D ratios (15), nocturnal dipping was defined according to our previously published definition in a similar adolescent patient population (14), in which N/D ratios were derived from a mean of the day and night systolic and diastolic values (14). Ratios were considered high when they were >1 SD above the mean for height- and gender-adjusted adolescent reference values (14). High N/D systolic ratio therefore was defined as >0.92, and high diastolic ratio was defined as >0.86. Nighttime was defined as 11:00 p.m. to 7:00 a.m.

Euglycemic conditions (blood glucose 4 to 6 mmol/L) were maintained for 10 to 12 h preceding and during all investigations. In both phases of the experiment, blood glucose was maintained by a modified glucose clamp technique as described previously (14). Female patients were studied during the early follicular phase of the menstrual cycle, determined by counting days of the menstrual cycle and measuring 17-estradiol levels. None of the female patients was a user of oral contraceptive medications.

Experiments were carried out on two separate days. Patients were admitted to the Clinical Investigation Unit at the Hospital for Sick Children the evening before each day of the study, as described previously (14). A 16-gauge peripheral venous cannula was inserted into a vein in one arm for infusion of glucose and insulin, and a second blood sampling line was inserted into a vein in the contralateral arm. Blood glucose was measured every hour, and the insulin infusion was adjusted to maintain euglycemia. Studies were conducted the following morning after an overnight fast with patients lying in the supine position in a warm, quiet room. A third intravenous line was inserted into the arm contralateral to the insulin infusion and was connected to a syringe infusion pump for infusions of inulin and paraaminohippurate (PAH) and AngII. Mean arterial pressure (MAP) and heart rate were measured before each blood sample throughout the study by an automated sphygmomanometer (Dinamapp, Criticon, Tampa, FL). After blood was collected for inulin and PAH blank, a priming infusion that contained 25% inulin (60 mg/kg) and 20% PAH (8 mg/kg) was administered. Thereafter, inulin and PAH were infused continuously at a rate calculated to maintain their respective plasma concentrations constant at 20 and 1.5 mg/dl. Patients remained supine at all times. After a 90-min equilibration period, blood was collected for inulin, PAH, and hematocrit (Hct). Blood was collected further every 30 min for 60 min, and GFR and effective renal plasma flow (ERPF) were estimated by steady-state infusion of inulin and PAH according to the calculation method described by Schnurr et al. (16).

A solution of AngII (Clinalfa, Läufelfingen, Switzerland; 51.2 µg/vial) was prepared by dissolving the diluent in normal saline to produce a concentration of 100 µg/ml. Twenty-two milliliters of normal saline then was added to 0.22 ml of AngII solution to produce a concentration of 400 ng/ml. AngII was infused at two doses, 1 and 3 ng/kg per min, each dose for 30 min. Patients remained supine at all times. Blood was collected once during each AngII infusion period for Hct, inulin, and PAH. MAP was measured at the midpoint of each infusion. An additional collection of blood was obtained at the end of the AngII infusion, after a 30-min recovery period.

Patients then were initiated on enalapril (0.1 mg/kg per d for 1 wk and then 0.1 mg/kg twice daily for 2 wk). After a total of 21 d, patients were admitted to the Clinical Investigation Unit on day 2, were again rendered euglycemic as outlined above, and again underwent renal hemodynamic testing using inulin and PAH clearance.

Sample Collection and Analytical Methods
Blood samples that were collected for inulin and PAH determinations were centrifuged immediately at 3000 rpm for 10 min at 4°C. Plasma was separated, placed on ice, and then stored at –70°C before the assay. Inulin and PAH were measured in serum by colorimetric assays using anthrone and N-(1-naphthyl) ethylenediamine, respectively. The mean of the final two baseline clearance periods represent GFR and ERPF, expressed per 1.73 m². Filtration fraction (FF) was determined as the ratio of GFR to ERPF. Renal blood flow (RBF) was calculated by dividing the ERPF by (1 – Hct). Renal vascular resistance (RVR) was derived by dividing the MAP by the RBF. All renal hemodynamic measurements were adjusted for body surface area.

Urinary AER was determined from three timed overnight urine collections. Urinary albumin concentration was determined by immunoturbidimetry (17). Glycosylated hemoglobin (HbA_1c) was measured by HPLC.

Statistical Analyses
The data were analyzed on the basis of filtration status. Results are presented as mean ± SEM. Between-group comparisons of all parameters at baseline were made using parametric methods (unpaired t test). Within-patient and between-group differences in the response to AngII and ACE inhibition were determined by repeated measures ANOVA with Bonferroni correction in the case of AngII and paired t test in the case of ACE inhibition. All statistical analyses were performed using the statistical package SAS (SAS Institute Inc., Cary, NC).

	Results

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
Baseline Characteristics
Eleven patients fulfilled the criteria for normofiltration (GFR 130 ml/min per 1.73 m²), and 11 patients fulfilled the criteria for hyperfiltration (GFR 135 ml/min per 1.73 m²). At baseline, the two groups were similar in age, gender distribution, body mass index, HbA_1c, and diabetes duration (Table 1). There were no differences in SBP, DBP, or MAP between the two groups. The proportion of patients with a nocturnal dipping BP pattern was not significantly different between the two groups, although there were a greater number of nondippers in the hyperfiltration group (Table 2). Ambulatory BP monitoring showed a significantly lower average 24-h SBP in the hyperfiltration group compared with the normofiltration group (Table 2). The hyperfiltration group exhibited a mean GFR of 177.7 ± 54.1 ml/min per 1.73 m² compared with a GFR of 111.3 ± 14.6 ml/min per 1.73 m² in the normofiltration group (P = 0.0008). FF also was augmented significantly in the hyperfiltration group (0.24 ± 0.03 versus 0.17 ± 0.03 in the normofiltration group; P = 0.009). No significant differences were noted in RBF or ERPF. Mean values for RVR were numerically lower in the hyperfiltration group compared with the normofiltration group, but the difference was not statistically significant (Table 2). The female participants had a mean 17-estradiol level of 62.0 ± 3.0 pmol/L at the time of the studies, consistent with the early follicular phase of the menstrual cycle.

View larger version (13K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 1. Change in GFR in response to renin angiotensin II (AngII) system modulation. *P < 0.05 for normofiltration versus hyperfiltration group. ACEI, angiotensin-converting enzyme inhibition.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

Diabetic hyperfiltration is thought to be due in part to RAS-mediated vasoconstriction, and experimental studies suggest that this may occur at the efferent arteriole, leading to an increase in intraglomerular pressure (2). In vitro studies have demonstrated that increased intraglomerular pressure, via shear-stress forces on the endothelium, can result in mesangial matrix formation and mesangial cell proliferation by increasing formation of types I and IV collagen, laminin, fibronectin, TGF-1, and AngII receptor mRNA (18–22). These factors then produce the characteristic mesangial matrix increase and eventually the sclerotic and irreversible glomerulopathy of diabetes (18–22). Several mechanisms, such as oxidative stress and activation of protein kinase C in addition to altered hemodynamic function, are seen as central to the pathogenesis of diabetic nephropathy (23). Human studies in type 1 diabetes have strongly correlated hyperfiltration with an increased risk for diabetic nephropathy in long-term observational studies (24,25).

Our first major finding was that after AngII infusion, the two groups showed different responses in GFR and FF as well as a quantitative difference in the reduction in RBF. The typical renal response to AngII is a decline in ERPF, maintenance of GFR, and an augmentation of FF (26). The normofiltration group responded in a normal manner, with maintenance of GFR despite a fall in ERPF. In contrast to the normofiltration group, the hyperfiltration group exhibited a significant decline in GFR accompanied by a fall in ERPF. Although these whole-kidney clearance studies do not allow us to discern specific alterations in segmental arteriolar resistances, one possible interpretation of the data is that the hyperfiltration group responded with a relatively greater increase in afferent resistance. Although the major experimental effect of AngII is efferent constriction (27), it also has been shown to have important afferent arteriolar vasoconstrictive effects at high concentrations in microperfused rabbit renal arterioles (28) and in studies that induce RAS blockade with ACE inhibition or angiotensin receptor blockade in rat arterioles (29). In addition, the vasoconstrictive effects of AngII may be modulated by vasodilatory mediators. For example, nitric oxide is thought to counteract RAS action, preventing RAS-mediated decreases in GFR (28). Nitric oxide upregulation has been associated with microalbuminuria (3) and with hyperfiltration in humans with type 1 diabetes without microalbuminuria (30). Vasodilatory prostaglandins (PG) such as PGI₂ also are thought to be important vasodilators in diabetes (4,31). The hyperfiltration that is induced by PG has been shown in rat models (32). In human studies, high urinary excretion of PGI₂ has been associated with hyperfiltration in type 1 diabetes (33). This suggests that vasodilation may contribute to the maintenance of hyperfiltration in subgroups of patients with type 1 diabetes.

The apparent vasoconstrictive response to AngII that was noted in this study in the hyperfiltration group may be indicative of a relative decrease in vasodilatory influences in the kidneys of these patients. However, this seems unlikely given the previously mentioned evidence of upregulation of vasodilatory factors in diabetes (3,4,30–33). A second possible explanation for this finding is that hyperfiltering patients may exhibit increased renal AngII receptor density. However, this, too, is unlikely because studies have shown a downregulation in these receptors (34,35). A third possible cause is a reduced tubuloglomerular feedback signal (36). The tubuloglomerular feedback hypothesis proposes that hyperfiltration has a primary tubular cause, beginning with increased sodium reabsorption in the proximal tubular, and resulting in decreased macula densa sodium chloride and ultimately a decrease in afferent resistance. However, AngII independently augments proximal tubular reabsorption of sodium (37), ultimately increasing rather than decreasing GFR. Nonetheless, it may be argued that in this context, proximal sodium reabsorption in response to the graded AngII infusion was impaired, resulting in increased macula densa sodium chloride concentration and afferent constriction. Last, the observed decline in GFR with AngII infusion also could have been on the basis of an AngII-mediated reduction in the glomerular ultrafiltration coefficient. Although our data do not allow us to differentiate between these various possibilities, we favor the view that, in the hyperfiltration group, vasodilatory influences were maximally stimulated and could not be upregulated further to counteract the pharmacologic doses of AngII.

Our second major observation was that RAS blockade with enalapril caused a significant reduction in GFR and FF in the hyperfiltration group but did not normalize the GFR under euglycemic conditions (6,38–40). RAS inhibition has been shown to decrease single-nephron GFR in diabetic rats using micropuncture studies, resulting in glomerular protection (41). This renoprotective effect likely is due, at least in part, to a reduction in intraglomerular pressure. Although hyperfiltering patients may have an upregulated RAS phenotype reflected by the partial response to RAS blockade, other influences also seem to have functional importance because GFR did not normalize. Our findings therefore suggest that RAS activation may not be the sole mediator of hyperfiltration in these diabetic patients; therefore, RAS inhibition ameliorates but does not correct this state. Although this study was not designed to address the clinical role of RAS blockade, the role of RAS blockade in similar patients with type 1 diabetes may be clarified by the ongoing Renin Angiotensin System Study (42,43).

Taken together, the incomplete amelioration of hyperfiltration in response to ACE inhibition and the decline in GFR in response to AngII suggest a significant role for arteriolar vasodilation in the maintenance of hyperfiltration in this group of patients. In support of a role for enhanced vasodilatory activity in the hyperfiltration group was the finding of a lower ambulatory SBP. Although speculative, this suggests that vasodilation also is important in the systemic circulation, as previously reported (44). It is important to note, however, that whatever the mechanisms that are responsible for these effects, ACE inhibitor–mediated reductions in GFR and FF seem to be blunted in these hyperfiltering adolescents with type 1 diabetes.

The divergent renal hemodynamic responses to RAS blockade in the two groups also deserve comment. As can be seen from Table 4, the responses of all parameters except MAP were directly opposite in the hyperfiltration group compared with the normofiltration group. Therefore, hyperfiltering patients with diabetes exhibit significantly different renal hemodynamic function when contrasted with patients with a normal GFR and are not merely the same patients with differences in extracellular fluid volume, protein intake, circulating glucose levels, and HbA_1c, these parameters having been controlled in our study. The two groups also exhibited subtle differences in their systemic BP: A greater number of nocturnal nondippers were found in the hyperfiltration group, although this did not reach statistical significance. Interpretation of this finding is limited by the small number of patients but may reflect underlying vascular dysfunction in this group, predisposing them to the earlier development of such complications as microalbuminuria (15,45).

This study has important limitations. The sample size was small, which may have limited our ability to detect significant differences in some parameters, such as baseline RVR and AngII-mediated changes in FF and RVR. We attempted to minimize the effect of the small sample size by using homogeneous study groups and by careful prestudy dietary preparation. Furthermore, the effect of variations in estrogen on renal hemodynamic and RAS function in female patients was controlled by studying only those who were nonusers of oral contraceptive medications and only during the follicular (low estrogen) phase of the menstrual cycle. We also used a study design that allowed each patient to act as his or her own control, thereby decreasing variability. We did not have a hyperfiltration group to use as a control (without RAS modulation), and the possibility exists that the GFR response to RAS modulation represented regression toward the mean. This is unlikely, however, because the pattern of renal hemodynamic function was consistent with changes in renal vasomotor tone with RAS blockade and stimulation. Another potential limitation of this study is the dose and duration that were chosen for the ACE inhibitor therapy, in that a further reduction in hyperfiltration may have been achieved with a longer period or a higher dose of enalapril.

	Conclusion

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 
Our aim was to establish the relative importance of RAS activation in the maintenance of the hyperfiltration state in patients with type 1 diabetes. Our findings show that glomerular hyperfiltration during euglycemia is a critical determinant of the hemodynamic response to RAS modulation in patients with type 1 diabetes. Furthermore, vasodilatory influences may complement RAS activation in mediating the hyperfiltration state, so RAS blockade may not correct hyperfiltration in all patients with uncomplicated type 1 diabetes.

	Acknowledgments

 
This work was supported by an operating grant from the Canadian Institutes of Health Research (J.A.M.). D.Z.I.C. was supported by funding from The Kidney Research Scientist Core Education and National Training Program (sponsored by the Canadian Institutes of Health Research and Kidney Foundation of Canada) and the Clinician Scientist Program at the University of Toronto.

We thank the nurses in the Clinical Investigation Unit, Hospital for Sick Children, for invaluable assistance with the protocol. We also thank Clinalfa for providing AngII and PAH for these experiments.

	Footnotes

 
Published online ahead of print. Publication date available at www.jasn.org.

E.B.S. and D.Z.I.C. contributed equally to this work.

	References

Top Abstract Introduction Materials and Methods Results Discussion Conclusion References

 

1. Miller JA, Floras JS, Zinman B, Skorecki KL, Logan AG: Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. Clin Sci (Lond) 90 : 189–195, 1996[Medline]
2. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations. Am J Physiol 265 : F477–F486, 1993[Medline]
3. Chiarelli F, Cipollone F, Romano F, Tumini S, Costantini F, di Ricco L, Pomilio M, Pierdomenico SD, Marini M, Cuccurullo F, Mezzetti A: Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: Relation to glomerular hyperfiltration. Diabetes 49 : 1258–1263, 2000[Abstract]
4. Craven PA, Caines MA, DeRubertis FR: Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: Relationship to the hyperfiltration of early diabetes. Metabolism 36 : 95–103, 1987[CrossRef][Medline]
5. Ziyadeh FN: Mediators of diabetic renal disease: The case for TGF-beta as the major mediator. J Am Soc Nephrol 15[Suppl 1] : S55–S57, 2004
6. Miller JA: Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 10 : 1778–1785, 1999[Abstract/Free Full Text]
7. Anderson S, Vora JP: Current concepts of renal hemodynamics in diabetes. J Diabetes Complications 9 : 304–307, 1995[CrossRef][Medline]
8. Lansang MC, Hollenberg NK: Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes: Are the forces leading to vasodilation and vasoconstriction linked? Diabetes 51 : 2025–2028, 2002[Abstract/Free Full Text]
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy The Collaborative Study Group. N Engl J Med 329 : 1456–1462, 1993[Abstract/Free Full Text]
10. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 : 851–860, 2001[Abstract/Free Full Text]
11. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861–869, 2001[Abstract/Free Full Text]
12. Mathiesen ER, Hommel E, Giese J, Parving HH: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303 : 81–87, 1991[Abstract/Free Full Text]
13. Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S, Martin FI: Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: A 3-year placebo-controlled biopsy study. Metabolism 47[Suppl 1] : 12–15, 1998
14. Miller JA, Curtis JR, Sochett EB: Relationship between diurnal blood pressure, renal hemodynamic function, and the renin-angiotensin system in type 1 diabetes. Diabetes 52 : 1806–1811, 2003[Abstract/Free Full Text]
15. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D: Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347 : 797–805, 2002[Abstract/Free Full Text]
16. Schnurr E, Lahme W, Kuppers H: Measurement of renal clearance of inulin and PAH in the steady state without urine collection. Clin Nephrol 13 : 26–29, 1980[Medline]
17. Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A 82 : 5963–5967, 1985[Abstract/Free Full Text]
18. Malek AM, Gibbons GH, Dzau VJ, Izumo S: Fluid shear stress differentially modulates expression of genes encoding basic fibroblast growth factor and platelet-derived growth factor B chain in vascular endothelium. J Clin Invest 92 : 2013–2021, 1993[Medline]
19. Riser BL, Cortes P, Zhao X, Bernstein J, Dumler F, Narins RG: Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 90 : 1932–1943, 1992[Medline]
20. Harrap SB, Wang BZ, MacLellan DG: Renal transplantation between male and female spontaneously hypertensive rats. Hypertension 19 : 431–434, 1992[Abstract/Free Full Text]
21. Yasuda T, Kondo S, Homma T, Harris RC: Regulation of extracellular matrix by mechanical stress in rat glomerular mesangial cells. J Clin Invest 98 : 1991–2000, 1996[Medline]
22. Yasuda T, Akai Y, Kondo S, Becker BN, Homma T, Owada S, Ishida M, Harris RC: Alteration of cellular function in rat mesangial cells in response to mechanical stretch relaxation. Contrib Nephrol 118 : 222–228, 1996[Medline]
23. Caramori ML, Mauer M: Diabetes and nephropathy. Curr Opin Nephrol Hypertens 12 : 273–282, 2003[CrossRef][Medline]
24. Rudberg S, Persson B, Dahlquist G: Increased glomerular filtration rate as a predictor of diabetic nephropathy: An 8-year prospective study. Kidney Int 41 : 822–828, 1992[Medline]
25. Yip JW, Jones SL, Wiseman MJ, Hill C, Viberti G: Glomerular hyperfiltration in the prediction of nephropathy in IDDM: A 10-year follow-up study. Diabetes 45 : 1729–1733, 1996[Abstract]
26. Miller JA, Anacta LA, Cattran DC: Impact of gender on the renal response to angiotensin II. Kidney Int 55 : 278–285, 1999[CrossRef][Medline]
27. Yuan BH, Robinette JB, Conger JD: Effect of angiotensin II and norepinephrine on isolated rat afferent and efferent arterioles. Am J Physiol 58 : F741–F750, 1990
28. Ito S, Arima S, Ren YL, Juncos LA, Carretero OA: Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 91 : 2012–2019, 1993[Medline]
29. Ohishi K, Carmines PK, Inscho EW, Navar LG: EDRF-angiotensin II interactions in rat juxtamedullary afferent and efferent arterioles. Am J Physiol 263 : F900–F906, 1992[Medline]
30. O’Byrne S, Forte P, Roberts LJ 2nd, Morrow JD, Johnston A, Anggard E, Leslie RD, Benjamin N: Nitric oxide synthesis and isoprostane production in subjects with type 1 diabetes and normal urinary albumin excretion. Diabetes 49 : 857–862, 2000[Abstract]
31. Perico N, Benigni A, Gabanelli M, Piccinelli A, Rog M, De Riva C, Remuzzi G: Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats. Diabetes 41 : 533–538, 1992[Abstract]
32. Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL, Anderson S: Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107 : 889–898, 2001[Medline]
33. Viberti GC, Benigni A, Bognetti E, Remuzzi G, Wiseman MJ: Glomerular hyperfiltration and urinary prostaglandins in type 1 diabetes mellitus. Diabet Med 6 : 219–223, 1989[Medline]
34. Skorecki KL, Ballermann BJ, Rennke HG, Brenner BM: Angiotensin II receptor regulation in isolated renal glomeruli. Fed Proc 42 : 3064–3070, 1983[Medline]
35. Inman SR, Porter JP, Fleming JT: Reduced renal microvascular reactivity to angiotensin II in diabetic rats. Microcirculation 1 : 137–145, 1994[Medline]
36. Thomson SC, Vallon V, Blantz RC: Kidney function in early diabetes: The tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 286 : F8–F15, 2004[Abstract/Free Full Text]
37. Geibel J, Giebisch G, Boron WF: Angiotensin II stimulates both Na(+)-H+ exchange, Na+/HCO3– cotransport in the rabbit proximal tubule. Proc Natl Acad Sci U S A 87 : 7917–7920, 1990[Abstract/Free Full Text]
38. Tesfamariam B, Brown ML, Deykin D, Cohen RA: Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 85 : 929–932, 1990[Medline]
39. Taylor PD, Poston L: The effect of hyperglycaemia on function of rat isolated mesenteric resistance artery. Br J Pharmacol 113 : 801–808, 1994[Medline]
40. Bohlen HG, Lash JM: Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol 265 : H219–H225, 1993[Medline]
41. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77 : 1925–1930, 1986[Medline]
42. Drummond K, Mauer M: The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 51 : 1580–1587, 2002[Abstract/Free Full Text]
43. Mauer M, Drummond K: The early natural history of nephropathy in type 1 diabetes: I. Study design and baseline characteristics of the study participants. Diabetes 51 : 1572–1579, 2002[Abstract/Free Full Text]
44. Tooke JE: Microvascular function in human diabetes. A physiological perspective. Diabetes 44 : 721–726, 1995[Abstract]
45. Pecis M, Azevedo MJ, Moraes RS, Ferlin EL, Gross JL: Autonomic dysfunction and urinary albumin excretion rate are associated with an abnormal blood pressure pattern in normotensive normoalbuminuric type 1 diabetic patients. Diabetes Care 23 : 989–993, 2000[Abstract]

This article has been cited by other articles:

				D. Z.I. Cherney, V. Lai, J. W. Scholey, J. A. Miller, B. Zinman, and H. N. Reich Effect of Direct Renin Inhibition on Renal Hemodynamic Function, Arterial Stiffness, and Endothelial Function in Humans With Uncomplicated Type 1 Diabetes: A pilot study Diabetes Care, February 1, 2010; 33(2): 361 - 365. [Abstract] [Full Text] [PDF]

				D. Z.I. Cherney, A. Konvalinka, B. Zinman, E. P. Diamandis, A. Soosaipillai, H. Reich, J. Lorraine, V. Lai, J. W. Scholey, and J. A. Miller Effect of Protein Kinase C{beta} Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study Diabetes Care, January 1, 2009; 32(1): 91 - 93. [Abstract] [Full Text] [PDF]

				D. Z.I. Cherney, J. A. Miller, J. W. Scholey, T. J. Bradley, C. Slorach, J. R. Curtis, M. G. Dekker, R. Nasrallah, R. L. Hebert, and E. B. Sochett The Effect of Cyclooxygenase-2 Inhibition on Renal Hemodynamic Function in Humans With Type 1 Diabetes Diabetes, March 1, 2008; 57(3): 688 - 695. [Abstract] [Full Text] [PDF]

				M. L. Halperin, S. Cheema-Dhadli, S.-H. Lin, and K. S. Kamel Properties Permitting the Renal Cortex to Be the Oxygen Sensor for the Release of Erythropoietin: Clinical Implications Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1049 - 1053. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: ASN.2005080872v1 17/6/1703    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sochett, E. B. Articles by Miller, J. A. Search for Related Content PubMed PubMed Citation Articles by Sochett, E. B. Articles by Miller, J. A.